← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV14행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
U87 CAR-T (U87 CAR-T)
Shanghai Unicar-Therapy Bio-medici…·Pancreatic Cancer
1 trials
Overview
Program
U87 CAR-T
Overview
Company
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Overview
Modality
CGT
Overview
Target
Pancreatic Cancer
Overview
Indication
Pancreatic Cancer; Solid Tumor, Adult
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.. Previously, we discovered that human solid tumours, but not normal human tissues, preferentially overexpress interleukin-13Receptor alpha2, a high binding receptor for IL-13. To develop novel anti-cancer approaches, we constructed a chimeric antigen receptor construct using…
Clinical
Safety signal
Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.. Previously, we discovered that human solid tumours, but not normal human tissues, preferentially overexpress interleukin-13Receptor alpha2, a high binding receptor for IL-13. To develop novel anti-cancer approaches, we constructed a chimeric antigen receptor construct using…
Clinical
Program phase
PHASE_1